Free Trial

Mid Cap Stocks To Consider - August 19th

ProShares UltraPro Short QQQ logo with background

Key Points

  • Mid-cap stocks to consider this week include ProShares UltraPro Short QQQ, Viking Therapeutics, and American Airlines Group, highlighting their potential for both growth and stability.
  • ProShares UltraPro Short QQQ aims to deliver triple the inverse daily returns of the NASDAQ-100 Index, catering to bearish market conditions.
  • Viking Therapeutics is advancing its lead drug candidate, VK2809, in Phase IIb trials for treating metabolic disorders such as non-alcoholic steatohepatitis.
  • Need better tools to track ProShares UltraPro Short QQQ? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

ProShares UltraPro Short QQQ, Viking Therapeutics, Direxion Daily TSLA Bull 2X Shares, Opendoor Technologies, TeraWulf, Hims & Hers Health, and American Airlines Group are the seven Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of companies whose total market capitalization typically falls between about $2 billion and $10 billion, placing them between large-cap and small-cap firms. They tend to offer a blend of growth potential and relative stability, making them appealing to investors seeking moderate risk and return. These companies had the highest dollar trading volume of any Mid Cap stocks within the last several days.

ProShares UltraPro Short QQQ (SQQQ)

ProShares UltraPro Short QQQ (the Fund) seeks daily investment results, which corresponds to three times the inverse of the daily performance of the NASDAQ-100 Index (the Index). The Index includes 100 of the non-financial domestic and international issues listed on National Association of Securities Dealers Automated Quotation (NASDAQ) Stock Market.

Read Our Latest Research Report on SQQQ

Viking Therapeutics (VKTX)

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

Read Our Latest Research Report on VKTX

Direxion Daily TSLA Bull 2X Shares (TSLL)

Read Our Latest Research Report on TSLL

Opendoor Technologies (OPEN)

Opendoor Technologies Inc. operates a digital platform for residential real estate transactions in the United States. It buys and sells homes. The company's product offerings comprise sell to opendoor product that enables homeowners to sell their home directly to it and resell the home to a home buyer; list with opendoor product that allows customers to list their home on the MLS with opendoor and receive cash offer; and opendoor marketplace product that connects the home seller with an institutional or retail buyer.

Read Our Latest Research Report on OPEN

TeraWulf (WULF)

Read Our Latest Research Report on WULF

Hims & Hers Health (HIMS)

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Read Our Latest Research Report on HIMS

American Airlines Group (AAL)

American Airlines Group Inc., through its subsidiaries, operates as a network air carrier. The company provides scheduled air transportation services for passengers and cargo through its hubs in Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C., as well as through partner gateways in London, Doha, Madrid, Seattle/Tacoma, Sydney, and Tokyo.

Read Our Latest Research Report on AAL

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ProShares UltraPro Short QQQ Right Now?

Before you consider ProShares UltraPro Short QQQ, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares UltraPro Short QQQ wasn't on the list.

While ProShares UltraPro Short QQQ currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines